All In Biotech

Drug Trial Radar · NCT00049751

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Aug 15, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,000

Actual

Start

Sep 2002

Primary completion

Not stated

Sponsor

Lead sponsor
AbbottIndustry
Sponsor type
Industry
First posted
Nov 14, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).

Conditions

  • Rheumatoid Arthritis

Interventions

  • AdalimumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in disease activity score at visit week 12 as compared to baseline

Locations

54 sites in 1 country. Site status is shown where the registry gives one.

  • Thomas McGee, MD

    Mobile, Alabama

  • Desert Valley Medical

    Apple Valley, California

  • Kenneth Hsu, MD, Inc.

    Bakersfield, California

  • Rheumatology Clinic

    Los Angeles, California

  • Michael Harrington, MD

    Napa, California

  • Midori Jane Nishio, MD

    Walnut Creek, California

  • Naveen Raja, MD

    Whittier, California

  • Mountain Rheumatology

    Denver, Colorado

  • Division of Rheumatic Diseases/University of CT Health Center

    Farmington, Connecticut

  • New Haven Medical Group, PC

    New Haven, Connecticut

  • Norman Gaylis, MD

    Aventura, Florida

  • Mike Schweitz, MD

    West Palm Beach, Florida

  • Maurice McCarthy, MD

    Winter Haven, Florida

  • Intermountain Orthopedics

    Boise, Idaho

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • Loyola University Medical Center

    Maywood, Illinois

  • West Suburban Health Care

    Oak Park, Illinois

  • OSF Medical Group -Rheumatology

    Peoria, Illinois

  • Rockford Clinic, Clinical Research Department

    Rockton, Illinois

  • Pain Therapy Center

    Schaumburg, Illinois

  • Baton Rouge Clinic

    Baton Rouge, Louisiana

  • Thomas Pressly, MD

    Shreveport, Louisiana

  • Rheumatology Associates

    Portland, Maine

  • Northampton Internal Medicine Association

    Northampton, Massachusetts

  • Fallon Clinic Research

    West Boylston, Massachusetts

  • John Howland, MD

    Bay City, Michigan

  • Freeman Health Systems

    Joplin, Missouri

  • Peggy Schlesinger, MD

    Missoula, Montana

  • NJ Associates in Medicine

    Fair Lawn, New Jersey

  • Internal Medicine and Rheumatic Diseases

    Millburn, New Jersey

  • Placido Morano, MD

    Brooklyn, New York

  • NYU Hospital for Joint Disease

    New York, New York

  • Alan Kaell, MD

    Port Jefferson Station, New York

  • Carolina Bone and Joint, PA

    Monroe, North Carolina

  • Gordon Senter, MD Rheumatology, PA

    Salisbury, North Carolina

  • MedCenter One Health Systems

    Bismarck, North Dakota

  • University Hospital of Cleveland

    Beachwood, Ohio

  • Arthritis Clinic

    Canton, Ohio

  • STAT Research, Inc.

    Dayton, Ohio

  • Arthritis and Osteoporosis Clinic, LLC

    Bend, Oregon

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.